Qihan Biotech, a Hangzhou-based biotech startup focused on organ transplantation, announced on Monday that it has raised US$25.5 million in a series A+ funding round.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?